Six professional analysts say $7.2 million for Q3 revenues. I'll go with that. Anything better will be terrific. IMO those calling for $12M-$14M are shorts trying to boost expectations so that if revenues come in at $7M-$8M they can moan and groan.
Any words on OMS 721, OMS 824 restart and an EU Omidria partner will be welcome too.
Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria®-- Ensures Access to Benefits of Omidria for Cataract Patients, Surgeons and Facilities --
PR NEWSWIRE 5:00 AM ET 10/15/2015
"The OMIDRIAssure coverage and reimbursement support services for surgeons and facilities remove uncertainties about coding, billing, and coverage of Omidria. The "Equal Access" Patient Assistance and the "We Pay the Difference" Commercial Reimbursement Programs remove patients' financial barriers to accessing the drug. Under the "Equal Access" program, financially eligible uninsured and government-insured patients receive Omidria free of charge for use during surgery. For commercially insured patients, Omeros(OMER) through its "We Pay the Difference" program pays the facility, on behalf of the patient, the difference between the facility's acquisition cost for Omidria and the amount covered by the patient's insurance less a $30 patient responsibility."
Search OMIDRIAssure for the full news release
European Society of Medical Oncology
17th World Congress on Gastrointestinal Cancer
The European Society of Medical Oncology (ESMO)
gastrointestinal cancer meeting encompasses malignancies
affecting every component of the gastrointestinal
tract and aspects related to patient care, screening, diagnosis,
and the latest management options. This year’s
meeting, held from July 1 to July 4 in Barcelona, Spain,
attracted 3,200 oncologists and other medical professionals.
We review major sessions on metastatic colorectal
cancer and hepatocellular carcinoma, including
two focused on treatment of the elderly, a group usually
excluded from clinical trials.
Phase 1 Study of PV-10 for Chemoablation of
Hepatocellular Cancer and Cancer Metastatic
To The Liver
• Paul Goldfarb, MD, Sharp Clinical Oncology Research, San
In metastatic melanoma, a phase 2 study of locoregional
chemoablation with PV-10 (10% rose bengal solution) has
demonstrated high complete response rates and durable local
control; phase 3 testing is under way. The first results of phase 1
evaluation of PV-10 in patients with liver tumors (nonresectable
HCC or liver metastases) 1 cm or larger were presented in a
poster by Dr. Goldfarb.
"Arkansas Compounding Pharmacy Recalls Sterile Products"
Check out Medistat, a topical ophthalmic drug supplier, recalling ALL sterile products.
"Flagged in recent inspections for apparent safety lapses, a compounding pharmacy in Conway, Arkansas, is voluntarily recalling all lots of its sterile products for humans and animals that were distributed between March 14, 2015, and September 9, 2015, the US Food and Drug Administration (FDA) announced today.
The pharmacy, US Compounding, is taking the action "due to (FDA) concern over a lack of sterility assurance," the company said in a news release posted on the agency's website.
The recalled products for humans — the vast majority are injectables — include testosterone, corticosteroids, glycopyrrolate, fentanyl, and the vasodilator alprostadil. Also on the list are topical ophthalmic drugs. The products were distributed to patients and healthcare providers alike.
US Compounding advises clinicians to discontinue using the products, quarantine what they have in stock, and contact the company to discuss returning them."
My guess is they've done serious DD and know what many of us know, that OMER is a solid company from commercial product, management and pipeline standpoints.
On Friday Sept. 4th, Peter Demopulos, Greg's brother and an OMER Director, bought 3962 OMER shares on the open market at an average price of $12.68/share. Total cost was $50,238.
New/excellent article by Alan Ross at Trust Intelligence
Post #14 on his Omeros thread, title as above.
Lead in points .......
-Omeros has been increasingly volatile lately, at least partly due to a large short position.
-Lead product, Omidria sales exceeded analyst consensus expectations in Q2’15
-Analyst consensus is that Omeros has more than enough cash to finance activities through Q1 2016
-Analyst cash flow projections and current cash position indicate Omeros has no need to raise cash this year
-Analyst sum of the parts valuation estimate pipeline and the development platform is worth more than the current share price
-Omeros has a number of pending 2015 catalysts that can provide more cash and move the market